Department of Otolaryngology-Head and Neck Surgery, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy.
Department of Otolaryngology-Head and Neck Surgery, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy.
Eur J Surg Oncol. 2024 Sep;50(9):108473. doi: 10.1016/j.ejso.2024.108473. Epub 2024 Jun 5.
The aim of this multicenter study was to evaluate the effectiveness and safety of electrochemotherapy (ECT) for the treatment of mucosal tumors in the head and neck. A total of 71 patients with 84 nodules of different histologies in the oral cavity, pharynx and larynx treated by ECT were evaluated. The data were collected from the InspECT database from 10 participating centers throughout Europe. Primary and recurrent/secondary tumors of different histologies were treated. The overall response rate was 65 %, with a 33 % complete response rate with limited side effects. The response rates of the primary and secondary tumors were not different. However, smaller tumors responded better than tumors larger than 3 cm in diameter. Furthermore, the tumors that were treated with curative intent responded significantly better than those treated with palliative intent. This study demonstrated the feasibility, safety and effectiveness of ECT in a larger cohort of patients with mucosal lesions in the head and neck region. Based on the available data, ECT can be used for the treatment of recurrent and, in some cases, primary mucosal tumors located in the oral cavity, larynx, and pharynx. A better response was obtained in patients with smaller primary tumors treated with curative intent.
本多中心研究旨在评估电化学疗法(ECT)治疗头颈部黏膜肿瘤的有效性和安全性。共评估了 71 例患者,这些患者的口腔、咽和喉部有 84 个不同组织学类型的结节,采用 ECT 治疗。数据来自欧洲 10 个参与中心的 InspECT 数据库。治疗了不同组织学的原发性和复发性/继发性肿瘤。总体缓解率为 65%,完全缓解率为 33%,副作用有限。原发性和继发性肿瘤的缓解率没有差异。然而,小于 3cm 直径的肿瘤比大于 3cm 直径的肿瘤反应更好。此外,以治愈为目的治疗的肿瘤比以姑息为目的治疗的肿瘤反应更好。这项研究在更大的头颈部黏膜病变患者队列中证明了 ECT 的可行性、安全性和有效性。基于现有数据,ECT 可用于治疗复发性和某些情况下位于口腔、喉和咽的原发性黏膜肿瘤。以治愈为目的治疗较小的原发性肿瘤患者的反应更好。